Refine
Year of publication
Document Type
- Article (45) (remove)
Has Fulltext
- yes (45)
Is part of the Bibliography
- no (45)
Keywords
- liver transplantation (3)
- Cancer treatment (2)
- Hepatocellular carcinoma (2)
- Liver Transplantation (2)
- Tacrolimus (2)
- cirrhosis (2)
- hepatocellular carcinoma (2)
- invasion (2)
- AKT-mTOR pathway (1)
- Acute appendicitis (1)
- Becton Dickinson (1)
- Big five (1)
- Cancer chemotherapy (1)
- Carrier-bound fibrin sealant (1)
- Chronic kidney disease (1)
- Clinical trial (1)
- Collagen hemostat (1)
- Colorectal cancer (1)
- Computed axial tomography (1)
- Conventional Chemotherapeutic (1)
- Dental students (1)
- Diagnostic algorithm (1)
- Diagnostic dye (1)
- Digestive system (1)
- Digestive system procedures (1)
- Emotional intelligence (1)
- Emotional recognition (1)
- Empathy (1)
- Endoscopy (1)
- Estimated glomerular filtration rate (1)
- Extended donor criteria (1)
- FOXO3a (1)
- Gastric cancer (1)
- Glomerular Filtration Rate (1)
- HCC (1)
- Hashimoto’s thyroiditis (1)
- Hemostatics (1)
- IgG4-related disease (1)
- Ileostomy (1)
- Immune suppression (1)
- Immunology (1)
- Immunosuppression (1)
- Immunosuppressive Agents (1)
- Indeterminate biliary stricture (1)
- Interventional oncological treatment (1)
- Intestinal neoplasms (1)
- Intraoperative test (1)
- Laser interstitial thermal therapy (1)
- Lipid solution (1)
- Liver diseases (1)
- Liver resection (1)
- Liver transplantation (1)
- Medical education (1)
- Methicillin-resistant Staphylococcus aureus (1)
- Microwave ablation (1)
- Negative appendectomy rate (1)
- Older patient (1)
- Oncogenes (1)
- Oncologic surgery (1)
- Organ allocation (1)
- Pancreas transplantation (1)
- Patient Blood Management (1)
- Personality (1)
- Personality inventory (1)
- Radiation exposure (1)
- Randomized controlled trial (1)
- Rectal cancer (1)
- Regression analysis (1)
- Rejection (1)
- Risk-stratification (1)
- SW480 Cell (1)
- Sarcopenia (1)
- Self-expandable metal stents (1)
- Self-expandable metal stents complications (1)
- Simulated patients (1)
- Sphere Formation Assay (1)
- Surgical and invasive medical procedures (1)
- Surgical oncology (1)
- TACE (1)
- Transarterial chemoembolization (1)
- Transfusion (1)
- Tumor obstruction (1)
- Tumorsphere Formation (1)
- ablation (1)
- anti-EGFR therapy (1)
- antimicrobial stewardship (1)
- arm (1)
- bile duct stenosis (1)
- biliary stricture (1)
- carbapenem resistance (1)
- chemorefractory metastatic colorectal cancer (1)
- complementary and alternative medicine (1)
- death rates (1)
- differentiated thyroid carcinoma (1)
- endoscopic retrograde cholangiopancreatography (1)
- endoscopy (1)
- enterobacter infections; pseudomonas aeruginosa; epidemiology (1)
- eosinophilic cholangitis (1)
- epidemiology (1)
- follow-up (1)
- growth (1)
- infection control (1)
- integrins (1)
- intraperitoneal therapy (1)
- liver metastases (1)
- medical risk factors (1)
- multidrug resistance (1)
- neoplasms (1)
- overall survival (1)
- perioperative mortality (1)
- peritoneal carcinomatosis (1)
- phase 2 clinical trials (1)
- platelet count (1)
- portal hypertension (1)
- pressurized intraperitoneal aerosol chemotherapy (PIPAC) (1)
- primary sclerosing cholangitis (1)
- progressive neoplastic disease (1)
- proliferation (1)
- pseudomonas aeruginosa (1)
- radiofrequency ablation (1)
- re-exposure (1)
- rechallenge (1)
- recurrent cholangitis (1)
- reintroduction (1)
- renal cell carcinoma (1)
- short-course antibiotic therapy (1)
- sirtuin1 (1)
- sorafenib (1)
- sulforaphane (1)
- thrombocytopenia (1)
- thrombocytosis (1)
- transmission (1)
- treatment (1)
- upper gastrointestinal cancer (1)
- vitamin D (1)
- vitamin D receptor (1)
- whole-genome sequencing (1)
Institute
- Medizin (45)
- Biochemie, Chemie und Pharmazie (1)
Objectives: Stenosis of the biliary anastomosis predisposes liver graft recipients to bacterial cholangitis. Antibiotic therapy (AT) is performed according to individual clinical judgment, but duration of AT remains unclear.
Methods: All liver graft recipients with acute cholangitis according to the Tokyo criteria grade 1 and 2 after endoscopic retrograde cholangiography (ERC) were included. Outcome of patients treated with short AT (<7 days) was compared to long AT (>6 days). Recurrent cholangitis (RC) within 28 days was the primary end point.
Results: In total, 30 patients were included with a median of 313 (range 34–9849) days after liver transplantation until first proven cholangitis. Among 62 cases in total, 51/62 (82%) were graded as Tokyo-1 and 11/62 (18%) as Tokyo-2. Overall median duration of AT was 6 days (1–14) with 36 cases (58%) receiving short AT and 26 (42%) receiving long AT. RC was observed in 10 (16%) cases, without significant difference in occurrence of RC in short versus long AT cases. CRP and bilirubin were significantly higher in patients with long AT, while low serum albumin and low platelets were associated with risk of RC.
Conclusion: A shorter antibiotic course than 7 days shows good results in selected, ERC-treated patients for post-transplantation biliary strictures.
Background: Protective effects of vitamin D have been reported in autoimmune and malignant thyroid diseases, though little is known about the underlying mechanism. Sirtuin 1 histon deacethylase (SIRT1) links the vitamin D pathway with regulation of transcription factor FOXO3a, a key player in cell cycle regulation and apoptosis. Aim of the present study was to investigate common single nucleotide polymorphisms (SNP's) in FOXO3a gene in respect to thyroid diseases, as well as to evaluate the hypothesis of Sirtuin1-FOXO3a interaction being a mediator of anti-proliferative vitamin D effects.
Methods: The SNP's FOXO3a rs4946936/rs4945816/rs9400239 were genotyped in 257 patients with differentiated thyroid carcinoma (DTC), 139 patients with Hashimoto thyroiditis (HT) and 463 healthy controls (HC). Moreover, T-helper cells of HC and papillary thyroid cancer cell line BCPAP were incubated with 1,25(OH)2D3 and/or SIRT1 inhibitor Ex-527 in order to elucidate SIRT1- dependent vitamin D effects on cell proliferation and FOXO3a gene expression in vitro.
Results: Patients with DTC tended to carry more often allele C in FOXO3a rs4946936 in comparison to HC (pcorrected = pc = 0.08). FOXO3a rs9400239T and rs4945816C was more frequent in HT in comparison to HC (pc = 0.02 and pc = 0.01, respectively). In both DTC and HT, we could not find a correlation of FOXO3a SNP's with vitamin D status. However, on in vitro level, 1,25(OH)2D3 showed an anti-proliferative effect in both T-helper cells and BCPAP, that was blocked by SIRT1 inhibition (T-helper cells: p = 0.0059, BCPAP: p = 0.04) and accompanied by elevated FOXO3a gene expression in T-helper cells (p = 0.05).
Conclusions: FOXO3a rs9400239T and rs4945816C may constitute risk factors for HT, independent of the vitamin D status.This indicates the implication of FOXO3a in pathogenesis of autoimmune thyroid diseases. The dependency of anti-proliferative vitamin D effects on SIRT1 activity further suggests a key role of vitamin D-SIRT1-FOXO3a axis for protective vitamin D effects.
Background and Aims. Systemic treatment with sorafenib has been the standard of care (SOC) in patients with advanced Barcelona Clinic Liver Cancer (BCLC) stage C hepatocellular carcinoma (HCC) for more than a decade. TACE has been reported to allow better local tumor control in selected patients with BCLC stage C HCC. Methods. A retrospective analysis of patients with BCLC stage C HCC that were treated with sorafenib and TACE was conducted; they were compared to BCLC stage C patients treated either with TACE or sorafenib in the same period of time outside a clinical trial. Results. A total of 201 patients with BCLC stage C were identified, who were treated with either sorafenib and TACE (group A; n = 54), sorafenib (group B; n = 82) or TACE (group C; n = 65). No significant difference in baseline characteristics was observed. Time to progression was 7.0 months (95% CI: 4.3–9.7), 4.1 months (95% CI: 3.6–4.7) and 5.0 months (95% CI: 2.9–7.1) in groups A, B and C, respectively, and overall survival was 16.5 months (95% CI: 15.0–18.1), 8.4 months (95% CI: 6.0–10.8) and 10.5 months (95% CI: 7.5–13.6), respectively (group A vs. group B: p < 0.001; group A vs. group C: p = 0.0023). Adverse events of grade 3/4 occurred in 34% of patients in group A. Conclusions. Although sorafenib is a SOC in patients with BCLC stage C HCC, TACE is frequently used as an additional locoregional treatment in selected patients. This combined approach resulted in a significant overall survival benefit in selected patients, although randomized trials have not yet proven this benefit.
Background: Intestinal perforation or leakage increases morbidity and mortality of surgical and endoscopic interventions. We identified criteria for use of full-covered, extractable self-expanding metal stents (cSEMS) vs. "Over the scope"-clips (OTSC) for leak closure.
Methods: Patients who underwent endoscopic treatment for postoperative leakage, endoscopic perforation, or spontaneous rupture of the upper gastrointestinal tract between 2006 and 2013 were identified at four tertiary endoscopic centers. Technical success, outcome (e.g. duration of hospitalization, in-hospital mortality), and complications were assessed and analyzed with respect to etiology, size and location of leakage.
Results: Of 106 patients (male: 75 (71%), female: 31 (29%); age (mean ± SD): 62.5 ± 1.3 years, 72 (69%) were treated by cSEMS and 34 (31%) by OTSC. For cSEMS vs. OTSC, mean treatment duration was 41.1 vs. 25 days, p<0.001, leakage size 10 (1-50) vs. 5 (1-30) mm (median (range)), and complications were observed in 68% vs. 8.8%, p<0.001, respectively. Clinical success for primary interventional treatment was observed in 29/72 (40%) vs. 24/34 (70%, p = 0.006), and clinical success at the end of follow-up was 46/72 (64%) vs. 29/34 (85%) for patients treated by cSEMS vs. OTSC; p = 0.04.
Conclusion: OTSC is preferred in small-sized lesions and in perforation caused by endoscopic interventions, cSEMS in patients with concomitant local infection or abscess. cSEMS is associated with a higher frequency of complications. Therefore, OTSC might be preferred if technically feasible. Indication criteria for cSEMS vs. OTSC vary and might impede design of randomized studies.
Introduction Occurrence of inaccurate or delayed diagnoses is a significant concern in patient care, particularly in emergency medicine, where decision making is often constrained by high throughput and inaccurate admission diagnoses. Artificial intelligence-based diagnostic decision support system have been developed to enhance clinical performance by suggesting differential diagnoses to a given case, based on an integrated medical knowledge base and machine learning techniques. The purpose of the study is to evaluate the diagnostic accuracy of Ada, an app-based diagnostic tool and the impact on patient outcome.
Methods and analysis The eRadaR trial is a prospective, double-blinded study with patients presenting to the emergency room (ER) with abdominal pain. At initial contact in the ER, a structured interview will be performed using the Ada-App and both, patients and attending physicians, will be blinded to the proposed diagnosis lists until trial completion. Throughout the study, clinical data relating to diagnostic findings and types of therapy will be obtained and the follow-up until day 90 will comprise occurrence of complications and overall survival of patients. The primary efficacy of the trial is defined by the percentage of correct diagnoses suggested by Ada compared with the final discharge diagnosis. Further, accuracy and timing of diagnosis will be compared with decision making of classical doctor–patient interaction. Secondary objectives are complications, length of hospital stay and overall survival.
Ethics and dissemination Ethical approval was received by the independent ethics committee (IEC) of the Goethe-University Frankfurt on 9 April 2020 including the patient information material and informed consent form. All protocol amendments must be reported to and adapted by the IEC. The results from this study will be submitted to peer-reviewed journals and reported at suitable national and international meetings.
Trial registration number DRKS00019098.